Beck, B.R., Shin, B., Choi, Y., et al. (2020) Predicting Commercially Available Antiviral Drugs That May Act on the Novel Coronavirus (SARS-CoV-2) through a Drug-Target Interaction Deep Learning Model. Computational and Structural Biotechnology Journal, 18, 784-790.
https://doi.org/10.1016/j.csbj.2020.03.025

has been cited by the following article:

• TITLE: Acute Kidney Injury Caused by Darunavir in a Patient with COVID-19: A Case Report

  AUTHORS: Shiema Abdalla, Lenah Elgassim, Fatima Rustom, Muftah Othman

  KEYWORDS: COVID-19, Darunavir, Acute Kidney Injury, SARS-CoV-2

  JOURNAL NAME: Open Journal of Nephrology, Vol.10 No.4, December 18, 2020

  ABSTRACT: Background: A highly contagious virus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a pandemic globally. HIV medications were one of the suggested treatments for Coronavirus disease 2019 (COVID-19). Here, we report an unusual adverse drug reaction with darunavir in a SARS-CoV-2-infected patient. Case Presentation: This is a case presentation of a 53-year-old male with no past medical history who was diagnosed with COVID-19. One week after initiating treatment, the patient developed acute kidney injury, and his serum creatinine increased significantly. Conclusion: As there was no clear justification for renal impairment such as a prerenal or postrenal cause, acute kidney injury, possibly crystal-induced nephropathy, was considered an adverse drug reaction from darunavir.